CA2323060A1 - Detection of neoplasia by analysis of saliva - Google Patents
Detection of neoplasia by analysis of saliva Download PDFInfo
- Publication number
- CA2323060A1 CA2323060A1 CA002323060A CA2323060A CA2323060A1 CA 2323060 A1 CA2323060 A1 CA 2323060A1 CA 002323060 A CA002323060 A CA 002323060A CA 2323060 A CA2323060 A CA 2323060A CA 2323060 A1 CA2323060 A1 CA 2323060A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- type
- strandedness
- topology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 78
- 210000003296 saliva Anatomy 0.000 title claims abstract description 51
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 238000004458 analytical method Methods 0.000 title abstract description 17
- 230000009826 neoplastic cell growth Effects 0.000 title description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 312
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 295
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 295
- 238000000034 method Methods 0.000 claims abstract description 100
- 201000011510 cancer Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 17
- 210000004072 lung Anatomy 0.000 claims abstract description 16
- 239000002773 nucleotide Substances 0.000 claims description 68
- 125000003729 nucleotide group Chemical group 0.000 claims description 67
- 230000035772 mutation Effects 0.000 claims description 65
- 239000000523 sample Substances 0.000 claims description 63
- 238000009396 hybridization Methods 0.000 claims description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
- 108091092878 Microsatellite Proteins 0.000 claims description 32
- 230000003321 amplification Effects 0.000 claims description 30
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 30
- 230000000295 complement effect Effects 0.000 claims description 29
- 108091034117 Oligonucleotide Proteins 0.000 claims description 19
- 108700020796 Oncogene Proteins 0.000 claims description 16
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 11
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 101710113436 GTPase KRas Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 5
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 4
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 3
- 208000035269 cancer or benign tumor Diseases 0.000 claims 7
- 108010014186 ras Proteins Proteins 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 235
- 239000013615 primer Substances 0.000 description 47
- 210000000349 chromosome Anatomy 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 230000002285 radioactive effect Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 11
- 238000006116 polymerization reaction Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 210000003128 head Anatomy 0.000 description 9
- 230000004075 alteration Effects 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 102000043276 Oncogene Human genes 0.000 description 7
- 108700020978 Proto-Oncogene Proteins 0.000 description 7
- 102000052575 Proto-Oncogene Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 210000003739 neck Anatomy 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- -1 nucleoside triphosphates Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 208000032818 Microsatellite Instability Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 235000016795 Cola Nutrition 0.000 description 2
- 241001634499 Cola Species 0.000 description 2
- 235000011824 Cola pachycarpa Nutrition 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091092919 Minisatellite Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108700021042 biotin binding protein Proteins 0.000 description 2
- 102000043871 biotin binding protein Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 208000007183 sinonasal undifferentiated carcinoma Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical class CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004393 laryngeal mucosa Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/038,637 US6235470B1 (en) | 1993-11-12 | 1998-03-10 | Detection of neoplasia by analysis of saliva |
| US09/038,637 | 1998-03-10 | ||
| PCT/US1999/005220 WO1999046408A1 (en) | 1998-03-10 | 1999-03-10 | Detection of neoplasia by analysis of saliva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2323060A1 true CA2323060A1 (en) | 1999-09-16 |
Family
ID=21901047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002323060A Abandoned CA2323060A1 (en) | 1998-03-10 | 1999-03-10 | Detection of neoplasia by analysis of saliva |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6235470B1 (https=) |
| EP (1) | EP1062366B1 (https=) |
| JP (2) | JP2002505888A (https=) |
| AT (1) | ATE433498T1 (https=) |
| AU (1) | AU769035B2 (https=) |
| CA (1) | CA2323060A1 (https=) |
| DE (1) | DE69940969D1 (https=) |
| NO (1) | NO20004504L (https=) |
| WO (1) | WO1999046408A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114885938A (zh) * | 2022-02-25 | 2022-08-12 | 厦门迈威生物科技有限公司 | 一种浆膜腔积液脱落细胞保存液及其生产方法 |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235470B1 (en) * | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
| AU726045B2 (en) * | 1996-08-28 | 2000-10-26 | Johns Hopkins University School Of Medicine, The | Method for detecting cell proliferative disorders |
| US7888324B2 (en) * | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| MXPA04002659A (es) * | 2001-12-14 | 2004-06-18 | Zila Inc | Analisis molecular dirigido por tincion para pronostico y diagnostico de cancer. |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
| EP3351919A1 (en) | 2003-01-24 | 2018-07-25 | University of Utah | Methods of predicting mortality risk by determining telomere length |
| EP1730160A4 (en) * | 2004-03-17 | 2008-04-09 | Univ Johns Hopkins | Neoplasia diagnostic compositions and methods of use |
| US20050287558A1 (en) * | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
| ES2401114T3 (es) * | 2004-08-10 | 2013-04-17 | Genzyme Corporation | Modulación antisentido de la expresión de apolipoproteína B |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| WO2007133725A1 (en) * | 2006-05-12 | 2007-11-22 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| CA2682082A1 (en) * | 2007-03-24 | 2008-10-02 | Genzyme Corporation | Administering antisense oligonucleotides complementary to human apolipoprotein b |
| US20090023138A1 (en) * | 2007-07-17 | 2009-01-22 | Zila Biotechnology, Inc. | Oral cancer markers and their detection |
| WO2009015294A1 (en) | 2007-07-24 | 2009-01-29 | Wisconsin Alumni Research Foundation | Biomarkers for human papillomavirus-associated cancers |
| CN102439171B (zh) | 2008-12-22 | 2017-07-14 | 犹他大学研究基金会 | 单色多重定量pcr |
| EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
| ITBO20090554A1 (it) * | 2009-08-27 | 2011-02-28 | Maria Gabriella Fornaro | Metodo per individuare la predisposizione al carcinoma della prostata. |
| EP2553463B1 (en) * | 2010-03-26 | 2017-05-03 | Hongzhi Zou | Methods and materials for detecting colorectal neoplasm |
| AU2012340441A1 (en) | 2011-11-15 | 2014-05-29 | University Of Miami | Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma |
| EP2798091A4 (en) * | 2011-12-31 | 2015-08-12 | Telome Health Inc | MEASUREMENTS OF LARGE TELOMERS FROM STORAGE AND SAMPLE DETECTION DEVICE |
| CA2902916C (en) | 2013-03-14 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| CA2912216A1 (en) | 2013-05-22 | 2014-11-27 | Telomere Diagnostics, Inc. | Measures of short telomere abundance |
| CN120700143A (zh) | 2014-03-31 | 2025-09-26 | 梅奥医学教育和研究基金会 | 检测结直肠赘生物 |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| WO2016108954A1 (en) | 2014-12-30 | 2016-07-07 | Telomere Diagnostics, Inc. | Multiplex quantitative pcr |
| US10030272B2 (en) | 2015-02-27 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Detecting gastrointestinal neoplasms |
| US10435755B2 (en) | 2015-03-27 | 2019-10-08 | Exact Sciences Development Company, Llc | Detecting esophageal disorders |
| CN114574585A (zh) | 2015-08-31 | 2022-06-03 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| US10370726B2 (en) | 2016-04-14 | 2019-08-06 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
| JP7481804B2 (ja) | 2016-04-14 | 2024-05-13 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 高度膵異形成の検出 |
| JP7356349B2 (ja) | 2017-02-28 | 2023-10-04 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 前立腺癌検出 |
| JP7277460B2 (ja) | 2017-11-30 | 2023-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ | 乳癌の検出 |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| USD1034632S1 (en) * | 2022-05-03 | 2024-07-09 | SimpliSafe, Inc. | Display screen with graphical user interface |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| EP0390323B2 (en) | 1989-03-29 | 2012-08-08 | Johns Hopkins University | Detection of loss of the wild-type p53 gene |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| DK0489149T3 (da) | 1990-06-27 | 2001-12-27 | Univ Princeton | Prober til påvisning af mutant P53 |
| AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
| JP3633932B2 (ja) | 1992-04-01 | 2005-03-30 | ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン | 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬 |
| ATE198358T1 (de) | 1992-04-27 | 2001-01-15 | Dartmouth College | Detektion von gensequenzen in biologischen flüssigkeiten |
| US5561041A (en) | 1993-11-12 | 1996-10-01 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection by analysis of sputum |
| US6235470B1 (en) * | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
| CH686982A5 (fr) * | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| US5589579A (en) | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
| MXPA00009654A (es) * | 1994-08-31 | 2005-09-08 | Univ Johns Hopkins Med | Deteccion de secuencias de acidos nucleicos hipermutables en tejidos. |
| AU726045B2 (en) * | 1996-08-28 | 2000-10-26 | Johns Hopkins University School Of Medicine, The | Method for detecting cell proliferative disorders |
| DE19712332A1 (de) * | 1997-03-25 | 1998-10-01 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Mikrosatelliten-Instabilität zur Tumordiagnostik |
| CA2285384C (en) * | 1997-03-28 | 2012-10-16 | Epitope, Inc. | Simultaneous collection of dna and non-nucleic analytes from oral fluids |
-
1998
- 1998-03-10 US US09/038,637 patent/US6235470B1/en not_active Expired - Lifetime
-
1999
- 1999-03-10 EP EP99911289A patent/EP1062366B1/en not_active Expired - Lifetime
- 1999-03-10 CA CA002323060A patent/CA2323060A1/en not_active Abandoned
- 1999-03-10 AT AT99911289T patent/ATE433498T1/de not_active IP Right Cessation
- 1999-03-10 DE DE69940969T patent/DE69940969D1/de not_active Expired - Lifetime
- 1999-03-10 AU AU29969/99A patent/AU769035B2/en not_active Expired
- 1999-03-10 JP JP2000535774A patent/JP2002505888A/ja active Pending
- 1999-03-10 WO PCT/US1999/005220 patent/WO1999046408A1/en not_active Ceased
-
2000
- 2000-09-08 NO NO20004504A patent/NO20004504L/no unknown
-
2001
- 2001-05-22 US US09/863,806 patent/US20020197608A1/en not_active Abandoned
-
2004
- 2004-01-05 JP JP2004000679A patent/JP2004159661A/ja active Pending
- 2004-01-09 US US10/754,478 patent/US7279312B2/en not_active Expired - Fee Related
-
2007
- 2007-10-08 US US11/868,683 patent/US7601521B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114885938A (zh) * | 2022-02-25 | 2022-08-12 | 厦门迈威生物科技有限公司 | 一种浆膜腔积液脱落细胞保存液及其生产方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004504D0 (no) | 2000-09-08 |
| ATE433498T1 (de) | 2009-06-15 |
| US6235470B1 (en) | 2001-05-22 |
| AU2996999A (en) | 1999-09-27 |
| EP1062366A1 (en) | 2000-12-27 |
| AU769035B2 (en) | 2004-01-15 |
| US20080124729A1 (en) | 2008-05-29 |
| AU2003266475A1 (en) | 2004-01-22 |
| NO20004504L (no) | 2000-11-08 |
| US20020197608A1 (en) | 2002-12-26 |
| DE69940969D1 (de) | 2009-07-23 |
| JP2002505888A (ja) | 2002-02-26 |
| HK1033765A1 (en) | 2001-09-21 |
| US7601521B2 (en) | 2009-10-13 |
| EP1062366B1 (en) | 2009-06-10 |
| EP1062366A4 (en) | 2002-05-08 |
| US20050009040A1 (en) | 2005-01-13 |
| JP2004159661A (ja) | 2004-06-10 |
| WO1999046408A1 (en) | 1999-09-16 |
| US7279312B2 (en) | 2007-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7601521B2 (en) | Detection of nucleic acid mutation associated with cancer by analysis of saliva | |
| US6177251B1 (en) | Method for detection of target nucleic acid by analysis of stool | |
| US6479234B1 (en) | Detection of hypermutable nucleic acid sequence in tissue and body fluids | |
| EP0728217B1 (en) | Nucleic acid mutation detection by analysis of sputum | |
| EP1690948A2 (en) | Methylation specific detection | |
| WO1996006951A9 (en) | Detection of hypermutable nucleic acid sequence in tissue | |
| HK1033765B (en) | Detection of neoplasia by analysis of saliva | |
| US7611841B2 (en) | Method for detecting methylation of promoter using restriction enzyme and DNA chip | |
| MXPA97001549A (en) | Detection of sequences of nucleic acids, hydrochlortable in teji |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDC | Discontinued application reinstated | ||
| FZDE | Discontinued |
Effective date: 20121217 |